Ireland
--:--IST
Latest
Clinical Trials in Turkey / NCT07346755
Recruiting Not applicable

Suprascapular Nerve Block and Proprioception in Hemiplegic Shoulder Pain: A Randomized Controlled Study

NCT07346755 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-05-01
Last updated
2026-01-21

Condition(s) studied

Hemiplegic Shoulder PainProprioceptionSuprascapular Nerve Block

Investigational drug(s) / intervention(s)

suprascapular nerve blockphysical therapy

suprascapular nerve block: An ultrasound-guided suprascapular nerve block will be performed by injecting 5 mL of 2% lidocaine (Lidon 100 mg/5 mL solution for injection) into the suprascapular fossa.

physical therapy: Accepted routine physical therapy modalities for hemiplegic shoulder pain, including cold pack application, transcutaneous electrical nerve stimulation, assisted shoulder range of motion exercises, and posterior capsule stretching exercises, will be administered five days per week for three weeks, in 45-minute sessions, for a total of 15 sessions

Study summary

The purpose of this prospective randomized controlled clinical trial is to evaluate the effect of suprascapular nerve block on shoulder joint proprioception in stroke patients with hemiplegic shoulder pain.

Fourteen patients aged 18-80 years with hemiplegic shoulder pain will be randomized into two groups. One group will receive suprascapular nerve block followed by a standardized physical therapy program, while the control group will receive the same physical therapy program alone.

The primary outcome is shoulder joint proprioception. Secondary outcomes include pain intensity, shoulder range of motion, motor recovery, stroke-specific quality of life, and upper extremity functional outcomes.

The results of this study are expected to clarify the role of suprascapular nerve block on proprioception and rehabilitation outcomes in patients with hemiplegic shoulder pain.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 18 and 80 years * Presence of shoulder pain on the hemiplegic side with a Numeric Rating Scale (NRS) score \> 3 * At least 1 month since the cerebrovascular event (subacute and chronic stroke patients) * Active shoulder flexion range of motion \> 90 degrees (required for the application of the laser pointer-assisted joint position sense test) * First-ever, unilateral hemiplegia Exclusion Criteria: * Mini-Mental State Examination score \< 24 indicating cognitive impairment * Presence of aphasia * Shoulder spasticity with a Modified Ashworth Scale score \> 2 * Brunnstrom upper extremity motor stage \< 3 * Botulinum toxin type A injection within the last 3 months to muscles affecting shoulder joint movement (trapezius, levator scapulae, pectoralis major, deltoid, serratus anterior, latissimus dorsi, rhomboids, teres major, biceps, coracobrachialis, triceps, supraspinatus, subscapularis, infraspinatus, and teres minor) * Pre-existing shoulder pathology causing pain in the hemiplegic shoulder * Presence of neglect syndrome * Complex regional pain syndrome, central pain, traumatic brachial plexus injury * Change in pain medication during the study period * Hypersensitivity to the medication used for suprascapular nerve block (lidocaine) * Adhesive capsulitis (frozen shoulder) * Other shoulder pathologies such as fractures or joint replacement

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fatih Sultan Mehmet Training and Research Hospital Istanbul, İstanbul, Turkey Istanbul Istanbul Recruiting

More Fatih Sultan Mehmet Training and Research Hospital trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07346755 on ClinicalTrials.gov ↗ ← All trials in Turkey